Literature DB >> 2240787

Effectiveness of arprinocid in the reduction of cryptosporidial activity in immunosuppressed rats.

J E Rehg1, M L Hancock.   

Abstract

Immunosuppressed rats inoculated with Cryptosporidium oocysts isolated from calves' feces were treated with arprinocid, 50 mg/kg of body weight/d. As determined from differences in the mean number of cryptosporidial developmental stages per villus in treated vs control rats, arprinocid had a substantial effect on cryptosporidial activity, which was parasitistatic instead of parasiticidal. Drug-ranging experiments indicated that arprinocid was effective at 50 and 25 mg/kg/d, but not at 12.5 mg/kg/d. These results suggest that further testing of arprinocid in different animal models, or in phase-I clinical trials, is warranted.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2240787

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  4 in total

1.  Validation of IMP dehydrogenase inhibitors in a mouse model of cryptosporidiosis.

Authors:  Suresh Kumar Gorla; Nina N McNair; Guangyi Yang; Song Gao; Ming Hu; Venkatakrishna R Jala; Bodduluri Haribabu; Boris Striepen; Gregory D Cuny; Jan R Mead; Lizbeth Hedstrom
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191

2.  Comparative evaluation of several techniques for purification of Cryptosporidium parvum oocysts from rat feces.

Authors:  P Suresh; J E Rehg
Journal:  J Clin Microbiol       Date:  1996-01       Impact factor: 5.948

3.  Specific serum and local antibody responses against Cryptosporidium parvum during medication of calves with halofuginone lactate.

Authors:  J E Peeters; I Villacorta; M Naciri; E Vanopdenbosch
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

4.  The effect of halofuginone lactate on experimental Cryptosporidium parvum infections in calves.

Authors:  M Naciri; R Mancassola; P Yvoré; J E Peeters
Journal:  Vet Parasitol       Date:  1993-01       Impact factor: 2.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.